Advances in laboratory testing for HIV

Pathology

Volumn 36, Issue 6, 2004, Pages 551-560

  Dax, Elizabeth M ^a   Arnott, Alicia ^a,b  

^a Natl Serology Ref Lab Australia   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Advances; Clinical management; Diagnostic testing; HIV; Immunoassay; Quality assurance; Screening; Viral load

Indexed keywords

CD4 ANTIGEN;

AUSTRALIA; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DISEASE COURSE; ENZYME ACTIVITY; ENZYME IMMUNOASSAY; FLOW CYTOMETRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOASSAY; LABORATORY TEST; NUCLEIC ACID ANALYSIS; PERFORMANCE; QUALITY CONTROL; QUANTITATIVE ANALYSIS; REVIEW; SCREENING TEST; SENSITIVITY AND SPECIFICITY; T LYMPHOCYTE; VIRUS CULTURE; VIRUS LOAD; VIRUS PATHOGENESIS; WESTERN BLOTTING;

EID: 11844251221     PISSN: 00313025     EISSN: None     Source Type: Journal    
DOI: 10.1080/00313020400010922     Document Type: Article

References (77)

1. Kleinman S, Busch MP, Hall L, et al. False-positive HIV-1 test results in a low-risk screening setting of voluntary blood donation. Retrovirus Epidemiology Donor Study. J Am Med Assoc 1998; 280: 1080-5.
2. Celum CL, Coombs RW, Jones M, et al. Risk factors for repeatedly reactive HIV-1 EIA and indeterminate western blots. A population-based case-control study. Arch Intern Med 1991; 154: 1129-37.
3. Mylonakis E, Paliou M, Lally M, et al. Laboratory testing for infection with the human immunodeficiency virus: established and novel approaches. Am J Med 2000; 109: 568-76.
4. World Health Organization. WHO recommendation for HIV antibody testing. Wkly Epidemiol Rec 1992; 67: 145-52.
5. Healey DS, Maskill WJ, Howard TS, et al. HIV-1 western blot: development and assessment of testing to resolve indeterminate reactivity. AIDS 1992; 6: 629-33.
6. Barre-Sinoussi F, Chermann JC, Rey F, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983; 220: 868-71.
7. Urnovitz HB, Sturge JC, Gottfried TD. Increased sensitivity of HIV-1 antibody detection. Nat Med 1997; 3: 1258.
8. Gurtler L, Muhlbacher A, Michl U, et al. Reduction of the diagnostic window with a new combined p24 antigen and human immunodeficiency virus antibody screening assay. J Virol Methods 1998; 75: 27-38.
9. Ly TD, Martin L, Daghfal D, et al. Seven human immunodeficiency virus (HIV) antigen-antibody combination assays: evaluation of HIV seroconversion sensitivity and subtype detection. J Clin Microbiol 2001; 39: 3122-8.
10. Dreier J, Gotting C, Wolff C, et al. Recent experience with human immunodeficiency virus transmission by cellular blood products in Germany: antibody screening is not sufficient to prevent transmission. Vox Sang 2002; 82: 80-3.
11. Weber B. HIV seroconversion: performance of combined antigen/antibody assays. AIDS 2003; 17: 931-933.
12. MMWR. Update: HIV counseling and testing using rapid tests-United States, 1995. MMWR Morb Mortal Wkly Rep 1998; 47: 211-5.
13. MMWR Advancing HIV prevention: new strategies for a changing epidemic-United States, 2003. MMWR Morb Mortal Wkly Rep 2003; 52: 329-32.
14. Tabor E, Epstein JS. NAT screening of blood and plasma donations: evolution of technology and regulatory policy. Transfusion 2002; 42: 1230-7.
15. Candotti D, Temple J, Owusu-Ofori S, et al. Multiplex real-time quantitative RT-PCR assay for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus type 1. J Virol Methods 2004; 118: 39-47.
16. Delwart EL, Kalmin ND, Jones TS, et al. First report of human immunodeficiency virus transmission via an RNA-screened blood donation. Vox Sang 2004; 86: 171-7.
17. Staszewski S, Demasi R, Hill AM, et al. HIV-1 RNA, CD4 cell count and the risk of progression to AIDS and death during treatment with HIV-1 reverse transcriptase inhibitors. AIDS 1998; 12: 1991-7.
18. Kim S, Hughes MD, Hammer SM, et al. Both serum HIV type 1 RNA levels and CD4+ lymphocyte counts predict clinical outcome in HIV type 1-infected subjects with 200 to 500 CD4+ cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. AIDS Res Hum Retroviruses 2000; 16: 645-53.
19. Schmitt Y. Performance characteristics of quantification assays for human immunodeficiency virus type 1 RNA. J Clin Virol 2001; 20: 31-3.
20. Gibellini D, Vitone F, Gori E, et al. Quantitative detection of human immunodeficiency virus type 1 (HIV-1) viral load by SYBR green real-time RT-PCR technique in HIV-1 seropositive patients. J Virol Methods 2004; 115: 183-9.
21. Lathey JL, Hughes MD, Fiscus SA, et al. Variability and prognostic values of virologic and CD4 cell measures in human immunodeficiency virus type 1-infected patients with 200-500 CD4 cells/mm(3) (ACTG 175). AIDS Clinical Trials Group Protocol 175 Team. J Infect Dis 1998; 177: 617-24.
22. Dezube BJ, Proper J, Zhang J, et al. A passive immunotherapy, (PE)HRG214, in patients infected with human immunodeficiency virus: a phase I study. J Infect Dis 2003; 187: 500-3.
23. Schreibman T, Friedland G. Use of total lymphocyte count for monitoring response to antiretroviral therapy. Clin Infect Dis 2004; 38: 257-62.
24. Storie I, Sawle A, Goodfellow K, et al. Perfect count: a novel approach for the single platform enumeration of absolute CD4+ T-lymphocytes. Cytometry 2004; 57B: 47-52.
25. Janossy G, Jani IV, Kahan M, et al. Precise CD4 T-cell counting using red diode laser excitation: for richer, for poorer. Cytometry 2002; 50: 78-85.
26. Zaunders JJ, Dyer WB, Wang B, et al. Identification of circulating antigen-specific CD4+ T lymphocytes with a CCR5+, cytotoxic phenotype in an HIV-1 long-term nonprogressor and in CMV infection. Blood 2004; 103: 2238-47.
27. Clavel F, Guetard D, Brun-Vezinet F, et al. Isolation of a new human retrovirus from West African patients with AIDS. Science 1986; 233: 343-6.
28. Korber BT, Osmanov S, Esparza J, et al. The World Health Organization Global Programme on AIDS proposal for standardization of HIV sequence nomenclature. WHO Network for HIV Isolation and Characterization. AIDS Res Hum Retroviruses 1994; 10: 1355-8.
29. Bock PJ, Markovitz DM. Infection with HIV-2. AIDS 2001; 15 (Suppl. 5): S35-45.
30. Reeves JD, Doms RW. Human immunodeficiency virus type 2. J Gen Virol 2002; 83: 1253-65.
31. Poulsen AG, Aaby P, Larsen O, et al. 9-year HIV-2-associated mortality in an urban community in Bissau, west Africa. Lancet 1997; 349: 911-4.
32. Pieniazek D, Ellenberger D, Janini LM, et al. Predominance of human immunodeficiency virus type 2 subtype B in Abidjan, Ivory Coast. AIDS Res Hum Retroviruses 1999; 15: 603-8.
33. Soriano V, Gomes P, Heneine W, et al. Human immunodeficiency virus type 2 (HIV-2) in Portugal: clinical spectrum, circulating subtypes, virus isolation, and plasma viral load. J Med Virol 2000; 61: 111-6.
34. Walther L, Putkonen P, Dias F, Biberfeld G, Thorstensson R. Evaluation of HIV-1/HIV-2 immunoblots for detection of HIV-2 antibodies. Clin Diagn Virol 1995; 4: 67-9.
35. Seed CR, Margaritis AR, Bolton WV, et al. Improved efficiency of national HIV, HCV, and HTLV antibody testing algorithms based on sequential screening immunoassays. Transfusion 2003; 43: 226-34.
36. Katsoulidou AS, Moschidis ZM, Gialeraki RE, et al. Clinical evaluation of an HIV-1 and HCV assay and demonstration of significant reduction of the HCV detection window before seroconversion. Transfusion 2004; 44: 59-66.
37. Le Corfec E, Le Pont F, Tuckwell HC, et al. Direct HIV testing in blood donations: variation of the yield with detection threshold and pool size. Transfusion 1999; 39: 1141-4.
38. Busch MP, Satten GA. Time course of viremia and antibody seroconversion following human immunodeficiency virus exposure. Am J Med 1997; 102: 117-24, discussion 125-6.
39. Dodd RY, Notari EP, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 2002; 42: 975-9.
40. Laperche S, Morel P, Deschaseaux M, et al. HIV antibody screening remains indispensable for ensuring viral safety of blood components despite NAT implementation. Transfusion 2003; 43: 1428-32.
41. Janvier D, Reviron M, Reviron J. False negative results in a competitive immunoassay for anti-HIV-antibodies due to the presence of rheumatoid factors. Vox Sang 1989; 56: 237-42.
42. Souza IE, Azevedo ML, Succi RC, et al. RNA viral load test for early diagnosis of vertical transmission of HIV-1 infection. J AIDS 2000; 23: 358-60.
43. Young NL, Shaffer N, Chaowanachan T, et al. Early diagnosis of HIV-1-infected infants in Thailand using RNA and DNA PCR assays sensitive to non-B subtypes. J AIDS 2000; 24: 401-7.
44. Rouet F, Montcho C, Rouzioux C, et al. Early diagnosis of paediatric HIV-1 infection among African breast-fed children using a quantitative plasma HIV RNA assay. AIDS 2001; 15: 1849-56.
45. Bulterys M, Jamieson DJ, O'Sullivan MJ, et al. Rapid HIV-1 testing during labor: a multicenter study. J Am Med Assoc 2004; 292: 219-23.
46. Minkoff H. Human immunodeficiency virus infection in pregnancy. Obstet Gynecol 2003; 101: 797-810.
47. Mcdonald AM, Li Y, Cruickshank MA, et al. Use of interventions for reducing mother-to-child transmission of HIV in Australia. Med J Aust 2001; 174: 449-52.
48. Arai H, Petchclai B, Khupulsup K, et al. Evaluation of a rapid immunochromatographic test for detection of antibodies to human immunodeficiency virus. J Clin Microbiol 1999; 37: 367-70.
49. Cohen MH, Olszewski Y, Branson B, et al. Using point-of-care testing to make rapid HIV-1 tests in labor really rapid. AIDS 2003; 17: 2121-4.
50. Forsyth BW, Barringer SR, Walls TA, et al. Rapid HIV testing of women in labor: too long a delay. J AIDS 2004; 35: 151-4.
51. Holguin A. Evaluation of three rapid tests for detection of antibodies to HIV-1 non-B subtypes. J Virol Methods 2004; 115: 105-7.
52. Steketee RW, Abrams EJ, Thea DM, et al. Early detection of perinatal human immunodeficiency virus (HIV) type 1 infection using HIV RNA amplification and detection. New York City Perinatal HIV Transmission Collaborative Study. J Infect Dis 1997; 175: 707-11.
53. Simonds RJ, Brown TM, Thea DM, et al. Sensitivity and specificity of a qualitative RNA detection assay to diagnose HIV infection in young infants. Perinatal AIDS Collaborative Transmission Study. AIDS 1998; 12: 1545-9.
54. Reisler RB, Thea DM, Pliner V, et al. Early detection of reverse transcriptase activity in plasma of neonates infected with HIV-1: a comparative analysis with RNA-based and DNA-based testing using polymerase chain reaction. J AIDS 2001; 26: 93-102.
55. Lambert JS, Harris DR, Stiehm ER, et al. Performance characteristics of HIV-1 culture and HIV-1 DNA and RNA amplification assays for early diagnosis of perinatal HIV-1 infection. J AIDS 2003; 34: 512-9.
56. Lambert JS. Maternal-fetal transmission of HIV-1 infection. Pediatr Ann 1993; 22: 413-6.
57. De Mendoza C, Holguin A, Soriano V. False positives for HIV using commercial viral load quantification assays. AIDS 1998; 12: 2076-7.
58. Rich JD, Merriman NA, Mylonakis E, et al. Misdiagnosis of HIV infection by HIV-1 plasma viral load testing: a case series. Ann Intern Med 1999; 130: 37-9.
59. Mylonakis E, Paliou M, Greenbough TC, et al. Report of a false-positive HIV test result and the potential use of additional tests in establishing HIV serostatus. Arch Intern Med 2000; 160: 2386-8.
60. Malmsten A, Shao XW, Aperia K, et al. HIV-1 viral load determination based on reverse transcriptase activity recovered from human plasma. J Med Virol 2003; 71: 347-59.
61. Wilson JW. Update on antiretroviral drug resistance testing: combining laboratory technology with patient care. AIDS Read 2003; 13: 25-30, 35-8.
62. Arens M. Clinically relevant sequence-based genotyping of HBV, HCV, CMV, and HIV. J Clin Virol 2001; 22: 11-29.
63. Sebastian J, Faruki H. Update on HIV resistance and resistance testing. Med Res Rev 2004; 24: 115-25.
64. Dunne AL, Mitchell FM, Coberly SK, et al. Comparison of genotyping and phenotyping methods for determining susceptibility of HIV-1 to antiretroviral drugs. AIDS 2001; 15: 1471-5.
65. Sayer DC, Land S, Gizzarelli L, et al. Quality assessment program for genotypic antiretroviral testing improves detection of drug resistance mutations. J Clin Microbiol 2003; 41: 227-36.
66. Larder BA, Kemp SD, Hertogs K. Quantitative prediction of HIV-1 phenotypic drug resistance from genotypes: The virtual phenotype. Antiviral Ther 2000; 5: 49.
67. Harrigan PR, Montaner JS, Wegner SA, et al. World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing. AIDS 2001; 15: 1671-7.
68. Janssen RS, Satten GA, Stramer SL, et al. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. J Am Med Assoc 1998; 280: 42-8.
69. Gouws E, Williams BG, Sheppard HW, et al. High incidence of HIV-1 in South Africa using a standardized algorithm for recent HIV seroconversion. J AIDS 2002; 29: 531-5.
70. Murphy G, Charlett A, Osner N, et al. Reconciling HIV incidence results from two assays employed in the serological testing algorithm for recent HIV seroconversion (STARHS). J Virol Methods 2003; 113: 79-86.
71. Young CL, Hu DJ, Byers R, et al. Evaluation of a sensitive/less sensitive testing algorithm using the bioMerieux Vironostika-LS assay for detecting recent HIV-1 subtype B' or E infection in Thailand. AIDS Res Hum Retroviruses 2003; 19: 481-6.
72. Chargelegue D, Stanley CM, O'Toole CM, et al. The absence of loss of antibodies of high affinity to human immunodeficiency virus (HIV) is associated with disease progression in HIV-1-infected patients. J Infect Dis 1995; 172: 897-8.
73. Suligoi B, Massi M, Galli C, et al. Identifying recent HIV infections using the avidity index and an automated enzyme immunoassay. J AIDS 2003; 32: 424-8.
74. Binley JM, Arshad H, Fouts TR, et al. An investigation of the high-avidity antibody response to glycoprotein 120 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 1997; 13: 1007-15.
75. Wilson KM, Croom HA, Richards K, Doughty L, Cunningham PH, Kemp BE, Branson BM, Johnson EIM, Dax EM. Incidence immunoassay for distinguishing recent from established HIV-1 infection in therapy naive populations. JAIDS (in press).
76. Ribas SG, Ondoa P, Schupbach J, et al. Performance of a quantitative human immunodeficiency virus type 1 p24 antigen assay on various HIV-1 subtypes for the follow-up of human immunodeficiency type 1 seropositive individuals. J Virol Methods 2003; 113: 29-34.
77. Mwaba P, Cassol S, Pilon R, et al. Use of dried whole blood spots to measure CD4+ lymphocyte counts in HIV-1-infected patients. Lancet 2003; 362: 1459-60.